Carly Levine

Carly Levine, PhD, is an Associate at the AMR Action Fund (AMRAF), where she is responsible for evaluating innovative technologies, cultivating investment opportunities, and supporting the fund’s portfolio companies across a wide range of initiatives. She joined AMRAF as an Analyst in November 2021 and has since guided numerous investments into clinical-stage biotechnology companies that are developing therapeutics or diagnostics for high-priority drug-resistant pathogens. Prior to joining AMRAF, she spent nearly a decade in academia, where she developed a deep understanding of the biology of drug resistance and the science that underpins novel antimicrobial development. She holds a PhD in microbiology and an MS in biomedical sciences from Rutgers University. She currently serves on the boards of BioVersys, Pattern Bioscience, and VenatorX Pharmaceuticals and has served on the boards of Antabio and Adaptive Phage Therapeutics.